Loading...
Thumbnail Image
Publication

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes [preprint]

Gutiérrez-González, Matias
Nanaware, Padma P.
Lu, Liying
Stern, Lawrence J.
DeKosky, Brandon J.
Embargo Expiration Date
Link to Full Text
Abstract

Human antibody responses are established by the generation of combinatorial sequence diversity in antibody variable domains, followed by iterative rounds of mutation and selection via T cell recognition of antigen peptides presented on MHC-II. Here, we report that MHC-II peptide epitope deletion from B cell receptors (BCRs) correlates with antibody development in vivo. Large-scale antibody sequence analysis and experimental validation of peptide binding revealed that MHC-II epitope removal from BCRs is linked to genetic signatures of T cell help, and donor-specific antibody repertoire modeling demonstrated that somatic hypermutation selectively targets the personalized MHC-II epitopes in antibody variable regions. Mining of class-switched sequences and serum proteomic data revealed that MHC-II epitope deletion is associated with antibody class switching and long-term secretion into serum. These data suggest that the MHC-II peptide epitope content of a BCR is an important determinant of antibody maturation that shapes the composition and durability of humoral immunity.

Source

bioRxiv 2021.01.15.426750; doi: https://doi.org/10.1101/2021.01.15.426750. Link to preprint on bioRxiv.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1101/2021.01.15.426750
PubMed ID
Other Identifiers
Notes

This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.

Full author list omitted for brevity. For the full list of authors, see article.

Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.